Pfizer (PFE) closed the most recent trading day at $24.48, moving +1.28% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.79%. Elsewhere, the Dow lost 0.26%, while the tech-heavy Nasdaq lost 1.55%.
Coming into today, shares of the drugmaker had lost 7.78% in the past month. In that same time, the Medical sector gained 5.5%, while the S&P 500 gained 4.28%.
Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to go public on August 4, 2026. The company is expected to report EPS of $0.68, down 12.82% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $14.45 billion, indicating a 1.39% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $2.96 per share and a revenue of $61.87 billion, demonstrating changes of -8.07% and -1.14%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.9% lower within the past month. As of now, Pfizer holds a Zacks Rank of #3 (Hold).
In the context of valuation, Pfizer is at present trading with a Forward P/E ratio of 8.17. This indicates a discount in contrast to its industry's Forward P/E of 16.41.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 32% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).